Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025703 | 0.91 | GRM2 (0.50) | GRM2ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL2022402 | 0.90 | GRM2 (0.44) | GRM2ALDH1A1KCNH2CHRM5TSHR | |
| SCHEMBL2027112 | 0.86 | ALDH1A1 (0.50) | GRM2ALDH1A1CHRM5TSHR | |
| SCHEMBL2026819 | 0.85 | ALDH1A1 (0.44) | GRM2ADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL2023238 | 0.84 | GRM2 (0.54) | GRM2ALDH1A1SCN9ACHRM5DRD4 | |
| SCHEMBL2024912 | 0.82 | GRM2 (0.40) | GRM2ALDH1A1FLT1KDRKCNH2 | |
| SCHEMBL2022427 | 0.81 | GRM2 (0.45) | GRM2ALDH1A1KCNH2CHRM5TSHR | |
| SCHEMBL2026320 | 0.80 | MEN1 (0.43) | GRM2ALDH1A1DRD4DRD2TSHR | |
| SCHEMBL2026154 | 0.79 | CHRM5 (0.49) | GRM2ALDH1A1KCNH2SCN5ASCN9A | |
| SCHEMBL27685012 | 0.79 | ALDH1A1 (0.38) | ADRA1DADRA1AADRA1BALDH1A1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885ADRA1D 68/4885ADRA1A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.